AIM ImmunoTech Gestion

Gestion contrôle des critères 3/4

Le PDG AIM ImmunoTech est Thomas Equels, nommé en Aug2015, a un mandat de 9.25 ans. La rémunération annuelle totale est $ 1.08M, composée du salaire de 78.6% et des bonus 21.4%, y compris les actions et options de la société. détient directement 2.36% des actions de la société, d'une valeur de $ 318.00K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 8.7 ans et 8.3 ans.

Informations clés

Thomas Equels

Directeur général

US$1.1m

Rémunération totale

Pourcentage du salaire du PDG	78.6%
Durée du mandat du directeur général	9.3yrs
Propriété du PDG	2.4%
Durée moyenne d'occupation des postes de direction	8.7yrs
Durée moyenne du mandat des membres du conseil d'administration	8.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Thomas Equels a-t-elle évolué par rapport aux bénéfices de AIM ImmunoTech?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$24m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$31m
Dec 31 2023	US$1m	US$850k	-US$29m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$19m
Dec 31 2022	US$1m	US$850k	-US$19m
Sep 30 2022	n/a	n/a	-US$21m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$2m	US$850k	-US$19m
Sep 30 2021	n/a	n/a	-US$17m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$3m	US$807k	-US$14m
Sep 30 2020	n/a	n/a	-US$12m
Jun 30 2020	n/a	n/a	-US$11m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	US$890k	US$703k	-US$9m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$10m
Mar 31 2019	n/a	n/a	-US$10m
Dec 31 2018	US$1m	US$751k	-US$10m
Sep 30 2018	n/a	n/a	-US$10m
Jun 30 2018	n/a	n/a	-US$8m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$987k	US$713k	-US$8m

Rémunération vs marché: La rémunération totale de Thomas ($USD 1.08M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 650.80K ).

Rémunération et revenus: La rémunération de Thomas a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Thomas Equels (71 yo)

9.3yrs

Titularisation

US$1,081,301

Compensation

Mr. Thomas K. Equels, Esq. M.S., J.D. serves as Director at BioFlorida Inc since August 2021. He serves as the Chief Executive Officer of AIM ImmunoTech Inc. (formerly known as Hemispherx Biopharma, Inc.)...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Thomas Equels	Executive Vice Chairman	9.3yrs	US$1.08m	2.36% $ 318.0k
Robert Dickey	Chief Financial Officer	2.6yrs	US$64.48k	0% $ 0
Peter Rodino	COO, Executive Director of Governmental Relations	8.1yrs	US$527.64k	0.63% $ 85.5k
Christopher McAleer	Scientific Officer	1.9yrs	pas de données	pas de données
Ann Marie Coverly	Director of Administration & Human Resources and Deputy Investor Relations Coordinator	11.8yrs	pas de données	pas de données
Ralph Cavalli	Vice President of QC & Manufacturing	14.6yrs	pas de données	pas de données

8.7yrs

Durée moyenne de l'emploi

70yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de AIM est chevronnée et expérimentée (8.7 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Thomas Equels	Executive Vice Chairman	16yrs	US$1.08m	2.36% $ 318.0k
Ronald H. Brus	Member of Scientific Advisory Board	no data	pas de données	pas de données
William Mitchell	Independent Chairman of the Board & Member of Scientific Advisory Board	26.3yrs	US$139.37k	0.12% $ 16.3k
Christopher Nicodemus	Member of Scientific Advisory Board	no data	pas de données	pas de données
Nancy Bryan	Independent Director	1.7yrs	US$93.75k	0.061% $ 8.2k
Stewart Appelrouth	Independent Director	8.3yrs	US$139.37k	0.38% $ 51.1k
W. Burnette	Chairman of Scientific Advisory Board	1.6yrs	pas de données	pas de données
Philip Roane	Member of Scientific Advisory Board	no data	pas de données	pas de données

8.3yrs

Durée moyenne de l'emploi

70yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de AIM sont considérés comme expérimentés (ancienneté moyenne 8.3 ans).

AIM ImmunoTech Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

Executive Vice Chairman recently bought US$50k worth of stock

Recent updates

New major risk - Financial position

Kellner Group Urges Immediate Change at AIM Immunotech Inc

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

AIM ImmunoTech Inc., Annual General Meeting, Dec 17, 2024

Price target increased by 19% to US$4.25

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $1.25632 million.

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Ted D. Kellner Sends a Notice to AIM ImmunoTech

Consensus EPS estimates fall by 15%

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Second quarter 2024 earnings released: US$0.035 loss per share (vs US$0.10 loss in 2Q 2023)

Todd Deutsch Sends Notice of Intent to Nominate Candidates to AIM ImmunoTech Board

AIM ImmunoTech Inc. Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of A Combination Therapy

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million.

AIM ImmunoTech Inc. has filed a Follow-on Equity Offering in the amount of $2.047668 million.

Consensus revenue estimates increase by 52%

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.076 loss in 1Q 2023)

AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

New minor risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AIM ImmunoTech Inc. to Report Q4, 2023 Results on Apr 02, 2024

Price target decreased by 30% to US$2.75

AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding

Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc., Annual General Meeting, Dec 29, 2023

AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions

Consensus EPS estimates fall by 12%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen

AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

AIM ImmunoTech Inc., Annual General Meeting, Dec 01, 2023

Kellner Group to Proceed with AIM Director Nominations and Proxy Solicitation

Consensus revenue estimates increase by 15%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc. Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin Phase 1B/2 Study Evaluating Ampligen®? (Rintatolimod) in Combination with Astrazeneca's Imfinzi (Durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Inc. Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

Price target decreased by 7.8% to US$4.92

Price target decreased by 7.7% to US$5.00

First quarter 2023 earnings released: US$0.076 loss per share (vs US$0.08 loss in 1Q 2022)

Consensus revenue estimates decrease by 83%, EPS upgraded

AIM ImmunoTech Inc. Announces the Netherlands Patent Office (Octrooicentrum Nederland) Grants A Utility Patent Covering Rugged dsRNA, A Double-Stranded RNA Product Related to Ampligen® (Rintatolimod)

Executive Vice Chairman recently bought US$50k worth of stock

AIM ImmunoTech Inc. Promotes Christopher McAleer from Deputy Scientific Officer to Scientific Officer

Aim Immunotech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

Consensus revenue estimates fall by 34%

Insufficient new directors

AIM ImmunoTech Inc. Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen

ASFV Committee Issues a Statement on Ruling in Delaware Action

ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action

Jonathan Thomas Jorgl Issues an Investor Presentation to Shareholders of AIM ImmunoTech

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech

AIM Immunotech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-Covid Conditions

Jonathan Thomas Jorgl Mails a Letter to Shareholders of AIM ImmunoTech

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc., Annual General Meeting, Nov 03, 2022

AIM ImmunoTech Inc. and Study Collaborator Roswell Park Commence Enrollment in an NCI-Funded Phase 2 Clinical Trial Evaluating Ampligen® (Rintatolimod) in Primary Pd-1/Pd-L1 Resistant Melanoma

Consensus revenue estimates fall by 23%

AIM ImmunoTech Inc. Announces Commencement of Phase 2 Study of Ampligen(R) for the Treatment of Pancreatic Cancer

Jonathan Jorgl Reiterates Intent to Proceed with Nominations and Proxy Solicitation

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

Jonathan Jorgl Provides Information to Shareholders of AIM ImmunoTech Inc

AIM ImmunoTech Reports Additional Patient Data from Single-Center Named Patient Program Evaluating Ampligen as Maintenance Therapy for Advanced Pancreatic Cancer Indicating Additional Progression-Free and Overall Survival over Previously Published Data

Consensus forecasts updated